A team of Rice University bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12)—a potent immune-boosting protein that holds promise for cancer treatment—loses effectiveness over time when used as an immunotherapeutic. The research challenges long-held assumptions about IL-12’s behavior in the body and offers a path toward safer and more effective dosing regimens.
Bioengineers shed light on dosing challenges for cancer immunotherapy
